BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Neuraltus Pharmaceuticals, Inc. 

2483 E. Bayshore Road
Suite 212
Palo Alto  California  94303   U.S.A.
Phone: 650-424-1600 Fax: 650-320-8504


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Results Highlighted At The 24th International Symposium On ALS/MND 12/9/2013 7:48:47 AM
Neuraltus Pharmaceuticals, Inc. Seeks $30 Million for New Lou Gehrig's Disease Drug Trial 10/10/2013 7:36:59 AM
Neuraltus Pharmaceuticals, Inc. Names Richard L. Casey as President and Chief Executive Officer 10/8/2013 6:22:20 AM
Cannabis Science Inc. Appoints Michael McGrath, MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine, University of California, San Francisco (UCSF), and Co-Founder of Biotechs Pathologica LLC and Neuraltus Pharmaceuticals, Inc., to the Company's Scientific Advisory Board 3/28/2013 6:36:33 AM
Neuraltus Pharmaceuticals, Inc. Announces Phase 2 Clinical Results for NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) 10/30/2012 9:42:34 AM
Andrew Gengos Out, John Walker in as Neuraltus Pharmaceuticals, Inc. CEO 9/12/2012 8:27:01 AM
Drug Developer Neuraltus Pharmaceuticals, Inc. Raises $9.6 Million Toward $11 Million Goal 12/22/2011 7:36:49 AM
Neuraltus Pharmaceuticals, Inc. Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease 12/3/2010 7:25:43 AM
Neuraltus Pharmaceuticals, Inc. Reports Clinical Results from Phase 1 NP001 Study in the Treatment of Amyotrophic Lateral Sclerosis (ALS) 11/30/2010 7:04:13 AM
Neuraltus Pharmaceuticals, Inc. Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP) 11/5/2010 11:32:19 AM
12